Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM3412 in Locally Advanced/Metastatic Solid Tumors
NCT06414460Phase 2Recruiting
- Sponsor
- Insilico Medicine
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ISM3412 in solid tumor (2 arms), sponsored by Insilico Medicine. Primary endpoints: Incidence of dose-limiting toxicity events at 31 days, Incidence and severity of adverse events at 30 months and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
ISM3412
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06414460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414460.